If NGIO's technology is the real deal as Joe has s
Post# of 36537
"Generex Biotechnology plans to file for Emergency Use Authorization(EUA) with the FDA for mass public vaccination this coming Fall.
Provides Update on the Development of an
Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic."
That headline would have gotten the market's attention.